Exciting Announcements from Innocan Pharma Corporation
Innocan Pharma Corporation (CSE: INNO) is making waves in the pharmaceutical world with its groundbreaking advancements in the field of veterinary medicine. Recently, the company announced remarkable results from a clinical study focusing on LPT-CBD, a liposomal form of synthetic cannabidiol. This innovative product has shown significant efficacy in providing pain relief for dogs suffering from osteoarthritis, and highlights Innocan's commitment to improving animal health.
Understanding the Clinical Study Results
In the published research article titled "Efficacy, pharmacokinetics and safety of liposomal synthetic cannabidiol injected subcutaneously in dogs: a randomized, blinded, placebo-controlled, crossover clinical trial," key findings emerged that reinforce LPT-CBD's potential. The study revealed a significant improvement in behavior and function among dogs administered LPT-CBD compared to those receiving the placebo, with an impressive 100% of dogs showing benefits from the treatment.
Details of the Study Design
The study comprised of eight client-owned dogs diagnosed with naturally occurring osteoarthritis. Designed as a randomized, blinded, crossover study, each dog received two subcutaneous injections—one of LPT-CBD at a dose of 7 mg/kg and a placebo consisting of empty liposomes. These injections were administered four weeks apart, with meticulous monitoring of the dogs’ condition through activity collars and assessments from veterinary specialists.
Outstanding Results of LPT-CBD Therapy
Owners of the dogs reported a significant reduction in lameness and pain following LPT-CBD administration, showcasing a marked improvement on both the Visual Lameness Scale and an interactive Visual Analog Scale. The sustained-release profile of LPT-CBD ensured measurable plasma CBD concentrations remained in the dogs' systems for up to four weeks after injection, further solidifying its effectiveness in pain alleviation.
Expert Insights on LPT-CBD
Professor Chezy Barenholz, who heads Innocan's Advisory Board, highlighted the promise of LPT-CBD, stating, "LPT-CBD has been repeatedly demonstrated to have a pain relief effect across multiple efficacy studies in dogs and other animals. However, this study is particularly important because it shows the clear advantages of LPT-CBD over the liposomal placebo.” This endorsement adds credibility to the findings and suggests a positive trajectory for further research.
Potential Market Impact
Dr. Eyal Kalo, Innocan's Vice President of Research and Development, also expressed enthusiasm about LPT-CBD's applications. The potential for LPT-CBD to serve as a long-acting pain management solution in both veterinary and human healthcare settings is significant. Ongoing discussions with regulatory bodies such as the FDA are being pursued to facilitate the advancement of this promising product across various markets.
About Innocan Pharma Corporation
Innocan has established itself as an innovator within the pharmaceutical and wellness sectors. The company specializes in a unique CBD-loaded liposome drug delivery platform aimed at providing safe pain management solutions without the risks commonly associated with opioids. Additionally, Innocan offers a range of high-performance self-care and beauty products aimed at promoting wellness. Through its subsidiary, BI Sky Global Ltd., Innocan is enhancing its capabilities in targeted online sales and expanding its reach in the competitive wellness market.
Contact Innocan Pharma
For further inquiries regarding Innocan Pharma Corporation, please reach out to:
Iris Bincovich, CEO
Phone: +1 5162104025
International: +972-54-3012842
UK: +442037699377
Frequently Asked Questions
What is LPT-CBD?
LPT-CBD is a liposomal form of synthetic cannabidiol designed to provide effective pain relief in various animal species.
What were the findings of the recent study on LPT-CBD?
The study indicated a significant improvement in pain and function for dogs treated with LPT-CBD compared to a placebo group.
How long do the effects of LPT-CBD last?
Results from the study suggested that LPT-CBD could provide sustained effects for up to four weeks following administration.
Is LPT-CBD safe for dogs?
All dogs in the study tolerated LPT-CBD well, with only minor, self-resolving adverse effects noted.
What is Innocan's focus moving forward?
Innocan is focused on advancing LPT-CBD for use in both veterinary and human markets while continuing to innovate within the pharmaceutical space.
